

WHAT IS CLAIMED IS:

July 13/02

1. A method of inhibiting inflammation in a host, the method comprising:
contacting said host with an effective dose of an inhibitor of integrin linked kinase.
- 5 2. The method according to Claim 1, wherein said inhibitor is an anti-sense
oligonucleotide that hybridizes with the nucleic acid sequence set forth in SEQ ID NO:1.
- 10 3. The method according to Claim 1, wherein said inhibitor comprises an ILK
specific antibody.
- 15 4. The method according to Claim 1, wherein said inhibitor comprises a small
organic molecule.
- 20 5. The method according to Claim 4, wherein said molecule blocks ILK catalytic
activity.
- 25 6. The method according to Claim 1, wherein said inhibitor decreases the
available level of [PtdIns (3,4,5) P₃] in a cell.
7. The method according to Claim 6, wherein said inhibitor is wortmannin.
8. The method according to Claim 6, wherein said inhibitor is LY294002.
9. The method of Claim 1, wherein cellular migration is inhibited.
- 25 10. A method of preventing inflammation in a host, the method comprising:
contacting said host with an effective dose of an inhibitor of integrin linked kinase.
- 30 11. The method according to Claim 10, wherein said inhibitor is an anti-sense
oligonucleotide that hybridizes with the nucleic acid sequence set forth in SEQ ID NO:1.
12. The method according to Claim 10, wherein said inhibitor comprises an ILK
specific antibody.

13. The method according to Claim 10, wherein said inhibitor comprises a small organic molecule.

14. The method according to Claim 13, wherein said molecule blocks ILK catalytic
5 activity.

15. The method according to Claim 10, wherein said inhibitor decreases the available level of [PtdIns (3,4,5) P₃] in a cell.

10 16. The method according to Claim 15, wherein said inhibitor is wortmannin.

17. The method according to Claim 15, wherein said inhibitor is LY294002.

18. The method of Claim 10, wherein cellular migration is inhibited.

15

add A¹
seq.